Key Details
Price
$3.34Annual ROE
-89.00%Beta
2.36Events Calendar
Next earnings date:
Mar 18, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Mar 18, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's chief Executive Officer, will participate in several upcoming investment conferences. Details are as follows:
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows:
The average of price targets set by Wall Street analysts indicates a potential upside of 273.1% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tenaya Therapeutics, Inc. (TNYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 217.6% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Two premium-laden buyouts sparked a wave of bargain hunting in biotech this week. Tenaya Therapeutics, a clinical-stage gene therapy company, was one of the industry's biggest winners.
FAQ
- What is the primary business of Tenaya Therapeutics?
- What is the ticker symbol for Tenaya Therapeutics?
- Does Tenaya Therapeutics pay dividends?
- What sector is Tenaya Therapeutics in?
- What industry is Tenaya Therapeutics in?
- What country is Tenaya Therapeutics based in?
- When did Tenaya Therapeutics go public?
- Is Tenaya Therapeutics in the S&P 500?
- Is Tenaya Therapeutics in the NASDAQ 100?
- Is Tenaya Therapeutics in the Dow Jones?
- When was Tenaya Therapeutics's last earnings report?
- When does Tenaya Therapeutics report earnings?
- Should I buy Tenaya Therapeutics stock now?